FDA approves BRYTLY as BTIG cuts Alcon stock target to USD 74
Published on 10/20/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSApproval, earnings and analyst targets
- The FDA approved BRYTLY on October 16, 2026 for redness relief lasting up to 12 hours.
- Second-quarter 2026 revenue reached USD 2.79 billion versus USD 2.56 billion consensus.
- BTIG cut its Alcon target to USD 74.00 from USD 82.00 on October 12, 2026.
Alcon (ISIN CH0432492467) won U.S. Food and Drug Administration approval for BRYTLY on October 16, 2026, adding a consumer eye drop to its vision-care portfolio. According to Alcon, the product is expected to reach major retailers and online stores in the coming months.
What does BRYTLY add?
BRYTLY works in one minute and is designed to reduce eye redness for up to 12 hours. Alcon says that duration is up to 50 percent longer than the eight-hour label claim for Lumify, giving the product a clear duration comparison in the over-the-counter market.
Three dated Alcon developments
On September 3, 2026, Alcon launched the UNITY M surgical microscope in the United States and Japan, according to MarketScreener. On October 7, 2026, Barclays began coverage with an Equal-Weight rating and a USD 70.00 target, as reported by SEPT Investing. On October 16, 2026, the FDA approved BRYTLY, completing the latest step in that sequence.
What do the latest figures show?
Alcon's second-quarter 2026 revenue reached USD 2.79 billion versus USD 2.56 billion consensus, an 8.98 percent premium, while adjusted earnings per share came to USD 0.84 versus USD 0.80 consensus, a 5.00 percent premium, according to SEPT Investing. The same report listed fiscal-year 2026 adjusted earnings-per-share guidance of USD 3.44 to USD 3.53, up from USD 3.38 to USD 3.47.
Next reporting date
MarketScreener lists November 10, 2026 as Alcon's next earnings release date for third-quarter 2026 results. That date gives investors the next scheduled checkpoint for the new product portfolio and the raised earnings outlook.
Market value sets the frame
Alcon's market capitalization stood at CHF 26.8 billion as of October 20, 2026. The valuation leaves the BRYTLY launch as a product expansion event rather than a separately quantified earnings contribution.
The further course of trading is shown by the continuously updated real-time quote of Alcon stock.
Alcon stock facts
- Company: Alcon Inc.
- ISIN: CH0432492467
- Ticker: ALC
- Primary exchange: SIX
- Market capitalization: CHF 26.8 billion (as of October 20, 2026)
- Sector / Industry: Health Care / Medical Equipment, Supplies and Distribution
Market context: Market report SMI.
